

Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma


SUPPLEMENTARY MATERIALS

Supplementary Table 1: Comparison of clinical characteristics according to tumour response

| Characteristics | | Tumour response | | <i>p</i> -value* |
|---------------------------|--------|------------------|----------------------|------------------|
| | | CR, <i>n</i> (%) | Non-CR, <i>n</i> (%) | |
| Gender | Male | 55 (91.7) | 5 (8.3) | 1.000 |
| | Female | 11 (100) | 0 (0) | |
| Age, years | <60 | 20 (90.9) | 2 (9.1) | 0.642 |
| | ≥60 | 46 (93.9) | 3 (6.1) | |
| Aetiology of LC | HBV | 53 (93.0) | 4 (7.0) | 1.000 |
| | Others | 13 (92.9) | 1 (7.1) | |
| Child–Pugh Classification | A | 64 (94.1) | 4 (5.9) | 0.199 |
| | B | 2 (66.7) | 1 (33.3) | |
| AFP, ng/mL | <10 | 41 (95.3) | 2 (4.7) | 0.376 |
| | ≥10 | 25 (89.3) | 3 (10.7) | |
| Tumour size, cm | <3 | 59 (92.2) | 5 (7.8) | 1.000 |
| | ≥3 | 7 (100) | 0 (0) | |
| AJCC stage | I–II | 61 (92.4) | 5 (7.6) | 1.000 |
| | IIIA | 5 (100) | 0 (0) | |
| BCLC stage | A | 41 (95.3) | 2 (4.7) | 0.367 |
| | B | 25 (89.3) | 3 (10.7) | |
| Pre-Tx to PBT site | No | 16 (100) | 0 (100) | 0.581 |
| | Yes | 50 (90.9) | 5 (9.1) | |
| Pre-Tx to other site | No | 10 (90.9) | 1 (9.1) | 0.581 |
| | Yes | 56 (6.7) | 4 (9.3) | |

Abbreviations: same as in Table 1.

*Fisher's exact test, two-tail.



Supplementary Figure 1: Patterns of treatment failure in all patients. Abbreviations: LR, local recurrence; IHR, intrahepatic recurrence; and DM, distant metastasis.